KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Announces Launch of Specialty Bracing Division

OrthoPediatrics Corp. Announces Launch of Specialty Bracing Division

WARSAW, Ind., Dec. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the launch of a new division, focused on non-surgical intervention for pediatric orthopedics. The OrthoPediatrics Specialty Bracing division (“OPSB”) will serve as a flagship house of brands and innovative products that expand the Company’s Total Addressable Market by approximately $600 million.

The Company first entered the non-operative space through the acquisition of MD Orthopaedics, Inc. (MDO) in 2022, and their bracing product lines and the patented Mitchell Ponseti® Ankle-Foot Orthosis (AFO) system for the treatment of clubfoot. Since the transaction, the Company has been aggressively building a portfolio of complementary products to address the large unmet needs for specialty bracing within the pediatric orthopedic market. Earlier this year, MDO acquired the assets of Rhino Pediatric Orthopedic Designs, Inc., a San Diego based company founded by two pediatric orthopedic surgeons. The Rhino™ “Kicker” and “Cruiser” braces were designed for children with Developmental Dysplasia of the hip.

Additionally, the Company announced the release of the DF2® Brace as part of its expansion in the non-surgical business for treating kids with musculoskeletal injuries. The DF2® Brace is intended for femur fracture fixation in pediatric patients from approximately 6 months to 5 years of age instead of spica cast by providing immobilization of the femur, knee, and hip. Most recently, the Company announced a new partnership with Montreal-based Ora Medical, to distribute The Levity, a gait-trainer device designed for children with walking difficulties.

OrthoPediatrics’ President of Trauma & Deformity Correction, Joe Hauser will also lead the new non-operative business, commenting, “We are excited for the launch of the new OPSB division, and our continued expansion into pediatric orthopedic non-surgical treatments for kids. This new addition advances our growth strategy of providing a broad product portfolio uniquely designed to treat children while surrounding pediatric orthopedic surgeons with the most comprehensive product offering in the market.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 53 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit

Investor Contact

Philip Trip Taylor

Gilmartin Group



415-937-5406



EN
06/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics to Participate in Upcoming Conferences

OrthoPediatrics to Participate in Upcoming Conferences WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in two upcoming investor conferences. Event: TD Cowen 46th Annual Health Care Conference Format: Fireside Chat Date: Tuesday, March 3, 2026Time: 1:10 pm ET Event: The Citizens Life Sciences Conference Format: Fireside Chat Date: Tuesday, March 10, 2026Time: 10:10 am ET An audio webcast of the ...

 PRESS RELEASE

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financ...

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results Record full year 2025 revenue of $236.3 million increased 15% compared to prior yearOperating Cash flow improvement of $22 million in full year 2025Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial resu...

 PRESS RELEASE

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Fina...

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. OrthoPediatrics will host a conference call on Thursday, February 26, 2026 at 4:30 p.m. ET to discuss the results. Inv...

 PRESS RELEASE

OrthoPediatrics Announces Expanded Enabling Technology Market Opportun...

OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older WARSAW, Ind., Feb. 03, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its partner, iotaMotion, has received FDA 510(k) clearance for expanded pediatric use of its iotaSOFT® Insertion System. The system is now cleared for ...

 PRESS RELEASE

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue fo...

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior yearInitiates guidance for record Adjusted EBITDA in 2026 WARSAW, Ind., Jan. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended December...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch